265989-36-4 Usage
Description
Tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-(4-hydroxyphenylcarbamoyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate is a complex organic compound with a unique molecular structure. It is characterized by its white solid appearance and serves as an intermediate in the synthesis of metabolites for Atorvastin, a drug used in the treatment of hypercholesterolemia.
Uses
1. Pharmaceutical Industry:
Tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-(4-hydroxyphenylcarbamoyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate is used as an intermediate in the synthesis of Atorvastin, a selective, competitive HMG-CoA reductase inhibitor. This drug is specifically indicated for lowering elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia.
2. Research and Development:
In the field of research and development, this compound may be utilized for further exploration of its chemical properties, potential applications, and possible modifications to enhance its therapeutic effects or develop new drugs based on its structure.
Chemical Properties:
Tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-(4-hydroxyphenylcarbamoyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate is a white solid, which indicates its stability and potential for use in various pharmaceutical formulations.
Check Digit Verification of cas no
The CAS Registry Mumber 265989-36-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,5,9,8 and 9 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 265989-36:
(8*2)+(7*6)+(6*5)+(5*9)+(4*8)+(3*9)+(2*3)+(1*6)=204
204 % 10 = 4
So 265989-36-4 is a valid CAS Registry Number.
InChI:InChI=1/C40H47FN2O6/c1-25(2)36-35(38(46)42-29-17-19-30(44)20-18-29)34(26-11-9-8-10-12-26)37(27-13-15-28(41)16-14-27)43(36)22-21-31-23-32(48-40(6,7)47-31)24-33(45)49-39(3,4)5/h8-20,25,31-32,44H,21-24H2,1-7H3,(H,42,46)/t31-,32-/m1/s1
265989-36-4Relevant articles and documents
Atorvastatin Derived HMG-CoA Reductase Degradation Inducing Compound
-
, (2020/12/01)
The present invention relates to a HMG-CoA reductase degradation-inducing compound and, more specifically, to a bifunctional compound in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked as HMG-CoA reductase binding moiety, to a production method thereof, to a HMG-CoA reductase degradation method using the same, and to a pharmaceutical composition for preventing or treating HMG-CoA reductase-related diseases, comprising the same.